TY  - JOUR
AU  - Heuser, Michael
AU  - Smith, B Douglas
AU  - Fiedler, Walter
AU  - Sekeres, Mikkael A
AU  - Montesinos, Pau
AU  - Leber, Brian
AU  - Merchant, Akil
AU  - Papayannidis, Cristina
AU  - Perez-Simon, Jose A
AU  - Hoang, Caroline J
AU  - O'Brien, Thomas
AU  - Ma, Weidong Wendy
AU  - Zeremski, Mirjana
AU  - O'Connell, Ashleigh
AU  - Chan, Geoffrey
AU  - Cortes, Jorge E
PY  - 2021
DO  - 10.1007/s00277-021-04465-4
UR  - http://hdl.handle.net/10668/17369
T2  - Annals of hematology
AB  - This analysis from the phase II BRIGHT AML 1003 trial reports the long-term efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study...
LA  - en
PB  - Springer
KW  - Acute myeloid leukemia
KW  - Clinical trial
KW  - Glasdegib
KW  - Secondary acute myeloid leukemia
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Benzimidazoles
KW  - Cytarabine
KW  - Female
KW  - Humans
KW  - Leukemia, Myeloid, Acute
KW  - Male
KW  - Middle Aged
KW  - Neoplasms, Second Primary
KW  - Phenylurea Compounds
KW  - Survival Analysis
KW  - Treatment Outcome
TI  - Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
TY  - research article
VL  - 100
ER  -